Altium Capital Management’s Regenxbio RGNX Stock Holding History

Altium Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-62,317	Closed	-$2.42M	–	150
2021 Q2	$2.42M	Buy	+62,317	New	+$2.23M	0.56%	73

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Altium Capital Management's RGNX Position: Q3 2021 in Review

Altium Capital Management sold out of Regenxbio (RGNX) in Q3 2021, closing a stake of 62,317 shares — an estimated $2.42M sold.

Altium Capital Management first reported a position in RGNX in Q2 2021 and held it in 1 quarter. The position peaked at $2.42M in Q2 2021. 182 funds tracked by Wall St. Rank hold RGNX as of Q3 2021.

Altium Capital Management reported no remaining Regenxbio position as of Q3 2021 after selling out during the quarter.
Altium Capital Management sold 62,317 Regenxbio shares in Q3 2021, an estimated $2.42M.
Altium Capital Management first reported a position in Regenxbio in Q2 2021 and held it in 1 quarter.
Altium Capital Management's Regenxbio position peaked at $2.42M in Q2 2021.
182 funds tracked by Wall St. Rank held Regenxbio as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.